{"id":61824,"date":"2026-03-30T15:51:30","date_gmt":"2026-03-30T07:51:30","guid":{"rendered":"https:\/\/flcube.com\/?p=61824"},"modified":"2026-03-30T15:51:31","modified_gmt":"2026-03-30T07:51:31","slug":"remegen-posts-89-revenue-surge-in-2025-returns-to-profitability-on-strength-of-taiai-and-disitamab-vedotin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61824","title":{"rendered":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin"},"content":{"rendered":"\n<p><strong>RemeGen Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA: 688331<\/a>) reported <strong>RMB 3.251 billion (USD 470 million) in 2025 revenue<\/strong>, a <strong>89.36% year-over-year increase<\/strong>, and swung to a <strong>net profit of RMB 710 million (USD 103 million)<\/strong>, marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014<strong>Tai\u2019ai\u00ae (telitacicept)<\/strong> for autoimmune diseases and <strong>disitamab vedotin<\/strong> in oncology\u2014both reinforced by <strong>National Reimbursement Drug List (NRDL) coverage<\/strong>. The company also secured a <strong>global out-licensing deal with Vor Biopharma<\/strong> for telitacicept, significantly boosting technology licensing income.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-highlights-2025\">Financial &amp; Operational Highlights (2025)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Amount (RMB)<\/th><th>Amount (USD)<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>\u00a53.251B<\/td><td>$470M<\/td><td>\u219189.4%<\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>\u00a5710M<\/td><td>$103M<\/td><td>Return to profitability<\/td><\/tr><tr><td><strong>Cash &amp; Notes<\/strong><\/td><td>\u00a51.493B<\/td><td>$216M<\/td><td>Strong liquidity<\/td><\/tr><tr><td><strong>Commercial Teams<\/strong><\/td><td>900 (autoimmune) + 500 (oncology)<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Hospital Coverage<\/strong><\/td><td>1,200 (Tai\u2019ai) \/ 1,050 (disitamab vedotin)<\/td><td>\u2014<\/td><td>Broad access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The revenue surge reflects successful commercial execution and strategic reimbursement wins.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-performance\">Core Product Performance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tai-ai-telitacicept-autoimmune-franchise\"><strong>Tai\u2019ai\u00ae (telitacicept)<\/strong> \u2013 Autoimmune Franchise<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Dual-target fusion protein inhibiting <strong>BLyS and APRIL<\/strong>, key cytokines in B-cell maturation<\/li>\n\n\n\n<li><strong>Approved Indications<\/strong>:<\/li>\n\n\n\n<li>Systemic lupus erythematosus (SLE)<\/li>\n\n\n\n<li>Myasthenia gravis (MG)<\/li>\n\n\n\n<li><strong>Generalized myasthenia gravis<\/strong> (approved May 2025)<\/li>\n\n\n\n<li><strong>Reimbursement<\/strong>: All indications included in <strong>2025 NRDL update<\/strong><\/li>\n\n\n\n<li><strong>Commercial Reach<\/strong>: Available in <strong>1,200 hospitals<\/strong> via dedicated 900-person team<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-disitamab-vedotin-oncology-franchise\"><strong>Disitamab Vedotin<\/strong> \u2013 Oncology Franchise<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type<\/strong>: HER2-targeting antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>NRDL-Covered Indications<\/strong>:<\/li>\n\n\n\n<li>Locally advanced or metastatic <strong>urothelial carcinoma<\/strong><\/li>\n\n\n\n<li><strong>HER2-positive gastric cancer<\/strong><\/li>\n\n\n\n<li><strong>Hospital Access<\/strong>: Distributed to <strong>1,050 hospitals<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-licensing-milestone\">Global Licensing Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partner<\/strong>: <strong>Vor Biopharma Inc.<\/strong> (U.S.)<\/li>\n\n\n\n<li><strong>Asset<\/strong>: <strong>Telitacicept<\/strong><\/li>\n\n\n\n<li><strong>Territory<\/strong>: <strong>Global rights excluding Greater China<\/strong><\/li>\n\n\n\n<li><strong>Deal Impact<\/strong>: Drove substantial <strong>technology licensing revenue<\/strong> in 2025<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: First major global partnership validating RemeGen\u2019s novel dual-cytokine inhibitor platform<\/li>\n<\/ul>\n\n\n\n<p>This deal positions telitacicept for potential expansion into <strong>U.S. and EU autoimmune markets<\/strong>, where BLyS\/APRIL inhibition remains a high-value therapeutic approach.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-positioning\">Market Positioning<\/h2>\n\n\n\n<p>RemeGen has successfully transitioned from a clinical-stage biotech to a <strong>vertically integrated commercial player<\/strong>:<br><strong>Dual-franchise model<\/strong>: Balanced growth across autoimmune and oncology<br><strong>Reimbursement leverage<\/strong>: NRDL inclusion drives volume adoption<br><strong>Global ambition<\/strong>: Out-licensing de-risks R&amp;D while funding internal pipeline<\/p>\n\n\n\n<p>With strong cash reserves and expanding hospital penetration, the company is well-positioned to sustain double-digit growth through 2026\u20132027.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding revenue sustainability, market access, and partnership execution. Actual results may vary due to competitive pressures, regulatory decisions, and reimbursement policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688331_20260328_LX2E.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688331_20260328_LX2E.\"><\/object><a id=\"wp-block-file--media-5e22bfb5-e93f-4f83-a183-ca1b19fb9c76\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688331_20260328_LX2E.pdf\">688331_20260328_LX2E<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688331_20260328_LX2E.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5e22bfb5-e93f-4f83-a183-ca1b19fb9c76\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1155,375,1294],"class_list":["post-61824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9995","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61824\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin\" \/>\n<meta property=\"og:description\" content=\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61824\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T07:51:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T07:51:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin\",\"datePublished\":\"2026-03-30T07:51:30+00:00\",\"dateModified\":\"2026-03-30T07:51:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824\"},\"wordCount\":382,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3005.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9995\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61824#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61824\",\"name\":\"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3005.webp\",\"datePublished\":\"2026-03-30T07:51:30+00:00\",\"dateModified\":\"2026-03-30T07:51:31+00:00\",\"description\":\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61824\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3005.webp\",\"width\":1080,\"height\":608,\"caption\":\"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61824#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61824","og_locale":"en_US","og_type":"article","og_title":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin","og_description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.","og_url":"https:\/\/flcube.com\/?p=61824","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T07:51:30+00:00","article_modified_time":"2026-03-30T07:51:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61824#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61824"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin","datePublished":"2026-03-30T07:51:30+00:00","dateModified":"2026-03-30T07:51:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61824"},"wordCount":382,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61824#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","keywords":["Finanical Reports","HKG: 9995","RemeGen","SHA: 688331"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61824#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61824","url":"https:\/\/flcube.com\/?p=61824","name":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61824#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61824#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","datePublished":"2026-03-30T07:51:30+00:00","dateModified":"2026-03-30T07:51:31+00:00","description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets\u2014Tai\u2019ai\u00ae (telitacicept) for autoimmune diseases and disitamab vedotin in oncology\u2014both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61824#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61824"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61824#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","width":1080,"height":608,"caption":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61824#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai\u2019ai and Disitamab Vedotin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61824"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61824\/revisions"}],"predecessor-version":[{"id":61827,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61824\/revisions\/61827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61826"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}